{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:11:06Z","timestamp":1792033866019,"version":"4.4.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016238","name":"Ministry of Economic Affairs and Climate Policy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016997","name":"Stichting Noaber Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jlr.2026.101088","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:10:51Z","timestamp":1782400251000},"page":"101088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mice with humanized FXR ligand-binding domain display distinct metabolic responses upon pharmacological FXR stimulation"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-9768","authenticated-orcid":false,"given":"Jinxiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde D.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Ustyantsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milaine V.","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels L.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Havinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8221-3178","authenticated-orcid":false,"given":"Nicolette","family":"Huijkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5040-0734","authenticated-orcid":false,"given":"Krisztina","family":"de Bruyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Weersing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels J.","family":"Kloosterhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Berezikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"van de Sluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7034-2861","authenticated-orcid":false,"given":"Henkjan J.","family":"Verkade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2518-737X","authenticated-orcid":false,"given":"Folkert","family":"Kuipers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Freark de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlr.2026.101088_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00010.2008","article-title":"Role of bile acids and bile acid receptors in metabolic regulation","volume":"89","author":"Lefebvre","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jlr.2026.101088_bib2","article-title":"Splice variants of metabolic nuclear receptors: relevance for metabolic disease and therapeutic targeting","volume":"1867","author":"Mukha","year":"2021","journal-title":"Biochim. Biophys. Acta BBA - Mol. Basis Dis."},{"key":"10.1016\/j.jlr.2026.101088_bib3","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bcp.2013.07.022","article-title":"Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition","volume":"86","author":"Vaquero","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jlr.2026.101088_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1074\/jbc.M209505200","article-title":"Natural structural variants of the nuclear receptor Farnesoid X receptor affect transcriptional activation","volume":"278","author":"Zhang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101088_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115028","article-title":"Hepatic farnesoid X-Receptor isoforms \u03b12 and \u03b14 differentially modulate bile salt and lipoprotein metabolism in mice","volume":"9","author":"Boesjes","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jlr.2026.101088_bib6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.molmet.2015.09.005","article-title":"Bioenergetic cues shift FXR splicing towards FXR\u03b12 to modulate hepatic lipolysis and fatty acid metabolism","volume":"4","author":"Correia","year":"2015","journal-title":"Mol. Metab."},{"key":"10.1016\/j.jlr.2026.101088_bib7","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1053\/j.gastro.2020.07.036","article-title":"FXR isoforms control different metabolic functions in liver cells via binding to specific DNA motifs","volume":"159","author":"Ramos Pittol","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jlr.2026.101088_bib8","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/hep.26187","article-title":"Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma","volume":"57","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2026.101088_bib9","article-title":"The farnesoid X receptor activates transcription independently of RXR at non-canonical response elements","volume":"53","author":"van der Veen","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jlr.2026.101088_bib10","first-page":"1","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jlr.2026.101088_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors","volume":"6","author":"Lu","year":"2000","journal-title":"Mol. Cell."},{"key":"10.1016\/j.jlr.2026.101088_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: the FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig. Dis. Basel Switz."},{"key":"10.1016\/j.jlr.2026.101088_bib13","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.0000178994.21828.a7","article-title":"The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism","volume":"25","author":"Claudel","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2026.101088_bib14","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jlr.2026.101088_bib15","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.3390\/ijms25115640","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease: from pathogenesis to Current therapeutic options","volume":"25","author":"Portincasa","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jlr.2026.101088_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/jcm11010004","article-title":"Modulation of bile acid metabolism to improve plasma lipid and lipoprotein profiles","volume":"11","author":"Zhang","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jlr.2026.101088_bib17","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1194\/jlr.M071183","article-title":"Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans","volume":"57","author":"Takahashi","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101088_bib18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1194\/jlr.RA119000243","article-title":"A human-like bile acid pool induced by deletion of hepatic Cyp2c70 modulates effects of FXR activation in mice","volume":"61","author":"de Boer","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101088_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1194\/jlr.RA119000395","article-title":"Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition","volume":"61","author":"Honda","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101088_bib20","doi-asserted-by":"crossref","first-page":"25963","DOI":"10.1074\/jbc.M200824200","article-title":"The amino acid residues asparagine 354 and isoleucine 372 of Human Farnesoid X receptor confer the receptor with high sensitivity to chenodeoxycholate","volume":"277","author":"Cui","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101088_bib21","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6\u03b1-Ethyl-Chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jlr.2026.101088_bib22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101088_bib23","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2026.101088_bib24","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1194\/jlr.M081935","article-title":"FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver","volume":"59","author":"Papazyan","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101088_bib25","article-title":"Short-term obeticholic acid treatment does not impact cholangiopathy in Cyp2c70-deficient mice with a human-like bile acid composition","volume":"1867","author":"Li","year":"2022","journal-title":"Biochim. Biophys. Acta BBA - Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.jlr.2026.101088_bib26","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1161\/ATVBAHA.118.311122","article-title":"Farnesoid X receptor activation by obeticholic acid elevates liver low-density lipoprotein receptor expression by mRNA Stabilization and reduces plasma low-density lipoprotein cholesterol in mice","volume":"38","author":"Singh","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2026.101088_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/oby.21701","article-title":"Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice","volume":"25","author":"Haczeyni","year":"2017","journal-title":"Obes. Silver Spring Md."},{"key":"10.1016\/j.jlr.2026.101088_bib28","article-title":"Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis","volume":"1865","author":"Carino","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.jlr.2026.101088_bib29","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.2147\/DDDT.S207277","article-title":"The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease","volume":"13","author":"Zhang","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jlr.2026.101088_bib30","doi-asserted-by":"crossref","first-page":"41930","DOI":"10.1074\/jbc.M306309200","article-title":"Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein","volume":"278","author":"Kok","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101088_bib31","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1101\/gr.234807.118","article-title":"Gene expression profiling of single cells from archival tissue with laser-capture microdissection and Smart-3SEQ","volume":"29","author":"Foley","year":"2019","journal-title":"Genome Res."},{"key":"10.1016\/j.jlr.2026.101088_bib32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinforma. Oxf. Engl."},{"key":"10.1016\/j.jlr.2026.101088_bib33","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.jlr.2026.101088_bib34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"Omics J. Integr. Biol."},{"key":"10.1016\/j.jlr.2026.101088_bib35","doi-asserted-by":"crossref","first-page":"i222","DOI":"10.1093\/bioinformatics\/btad264","article-title":"isONform: reference-free transcriptome reconstruction from Oxford Nanopore data","volume":"39","author":"Petri","year":"2023","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jlr.2026.101088_bib36","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jcmgh.2020.12.004","article-title":"Cholangiopathy and biliary fibrosis in Cyp2c70-Deficient mice are fully reversed by ursodeoxycholic acid","volume":"11","author":"De Boer","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jlr.2026.101088_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cmpb.2008.06.010","article-title":"BrightStat.com: free statistics online","volume":"92","author":"Stricker","year":"2008","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.jlr.2026.101088_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut Microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.jlr.2026.101088_bib39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.jlr.2026.101088_bib40","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12681","article-title":"Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers","volume":"18","author":"Pencek","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jlr.2026.101088_bib41","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jlr.2026.101088_bib42","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.jlr.2026.101088_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jlr.2026.101088_bib44","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1172\/JCI0214505","article-title":"Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element","volume":"109","author":"Claudel","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jlr.2026.101088_bib45","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1074\/jbc.M109.083899","article-title":"Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia","volume":"285","author":"Zhang","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101088_bib46","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jlr.2026.101088_bib47","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jlr.2026.101088_bib48","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol. Cell."},{"key":"10.1016\/j.jlr.2026.101088_bib49","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.jmedchem.1c00851","article-title":"Identification of betulinic acid derivatives as potent TGR5 agonists with antidiabetic effects via humanized TGR5H88Y mutant mice","volume":"64","author":"Yun","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jlr.2026.101088_bib50","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1021\/acs.jmedchem.5b00342","article-title":"Recent progress on bile acid receptor modulators for treatment of metabolic diseases","volume":"59","author":"Xu","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jlr.2026.101088_bib51","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/ncomms3384","article-title":"Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity","volume":"4","author":"Li","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jlr.2026.101088_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/joim.12140","article-title":"Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism","volume":"275","author":"Hu","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jlr.2026.101088_bib53","article-title":"Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice","volume":"6","author":"Kunst","year":"2024","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"10.1016\/j.jlr.2026.101088_bib54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.livres.2022.11.002","article-title":"Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis","volume":"6","author":"Matye","year":"2022","journal-title":"Liver Res."},{"key":"10.1016\/j.jlr.2026.101088_bib55","article-title":"The FXR agonist obeticholic acid does not stimulate liver regeneration in hepatectomized mice","author":"Mierlo","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.jlr.2026.101088_bib56","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.28712","article-title":"FXR activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption","volume":"64","author":"Xu","year":"2016","journal-title":"Hepatol. Baltim. Md."},{"key":"10.1016\/j.jlr.2026.101088_bib57","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1194\/jlr.M033423","article-title":"Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in Ldlr \u2212\/\u2212 mice versus hamsters","volume":"54","author":"Gard\u00e8s","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101088_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.111364","article-title":"Obeticholic acid aggravates liver fibrosis by activating hepatic farnesoid X receptor-induced apoptosis in cholestatic mice","volume":"406","author":"Lu","year":"2025","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.jlr.2026.101088_bib59","article-title":"Obeticholic acid induces hepatoxicity via FXR in the NAFLD mice","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jlr.2026.101088_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33070-1","article-title":"FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis","volume":"8","author":"van Golen","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jlr.2026.101088_bib61","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1126\/science.1121435","article-title":"Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration","volume":"312","author":"Huang","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jlr.2026.101088_bib62","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2022.08.054","article-title":"Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls","volume":"163","author":"Murillo Perez","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jlr.2026.101088_bib63","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1097\/HEP.0000000000001174","article-title":"Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): a trial emulation study design","volume":"81","author":"Brookhart","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2026.101088_bib64","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41575-022-00687-7","article-title":"Mechanisms of pruritus in cholestasis: understanding and treating the itch","volume":"20","author":"Beuers","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jlr.2026.101088_bib65","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3390\/ph18091424","article-title":"Obeticholic acid and other Farnesoid-X-Receptor (FXR) agonists in the treatment of liver disorders","volume":"18","author":"Fiorucci","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jlr.2026.101088_bib66","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70229","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of INT-787, a novel farnesoid X receptor agonist, in healthy volunteers: a phase 1 trial","volume":"18","author":"Capozza","year":"2025","journal-title":"Clin. Transl. Sci."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227526001148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227526001148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:37:01Z","timestamp":1791301021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227526001148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022227526001148"],"URL":"https:\/\/doi.org\/10.1016\/j.jlr.2026.101088","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mice with humanized FXR ligand-binding domain display distinct metabolic responses upon pharmacological FXR stimulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlr.2026.101088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"101088"}}